8-K - NVCR - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

May 31, 2025

Date of Report (date of earliest event reported)

NovoCure Limited

(Exact name of registrant as specified in its charter)

Jersey	001-37565		98-1057807
(State or other jurisdiction of incorporation or organization)	(Commission File Number)		(I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street	St. Helier	Jersey	JE2 4UF
(Address of Principal Executive Offices)			(Zip Code)

+44 (0) 15 3475 6700

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, no par value	NVCR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure

On May 31, 2025, NovoCure Limited (the "Company" or "Novocure"), issued a press release announcing that on that day it presented positive results from the phase 3 PANOVA-3 clinical trial ("PANOVA-3") evaluating the use of Tumor Treating Fields (TTFields) therapy with gemcitabine and nab-paclitaxel (GnP) for locally advanced pancreatic adenocarcinoma (LA-PAC) at the 2025 American Society of Clinical Oncology Annual Meeting ("ASCO 2025") and that the results will be simultaneously published in the Journal of Clinical Oncology. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The data provided at the presentation is attached hereto as Exhibit 99.2 and incorporated by reference herein. This data is available on the Company's investor relations page at www.novocure.com.

Also on May 31, 2025, the Company hosted an investor event that included a presentation and discussion of the results from PANOVA-3 that were presented at ASCO 2025. The data provided at the investor event is attached hereto as Exhibit 99.3 and incorporated by reference herein. This data is also available on the Company's investor relations page at www.novocure.com.

The PANOVA-3 data are expected to serve as the basis for a Premarket Approval (PMA) submission to the U.S. Food and Drug Administration in the second half of 2025.

The information contained in this Item 7.01 of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of NovoCure Limited, dated May 31, 2025
99.2	Presentation Data from ASCO 2025 dated May 31, 2025
99.3	Investor Event Presentation Data dated May 31, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited

(Registrant)

Date: June 2, 2025

By: /s/ Christoph Brackmann

Name: Christoph Brackmann

Title: Chief Financial Officer

Document

Exhibit 99.1

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial

The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer

Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology

Baar, Switzerland – May 31, 2025 - Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology.

“The data presented today from the PANOVA-3 trial of Tumor Treating Fields show a clinically meaningful and statistically significant improvement in overall survival for people with locally advanced pancreatic cancer,” said Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial. “Importantly, we also saw an extension in the duration of time before pain progressed. Pain is a hallmark of this disease, and as a clinician, the potential of this therapy to address this aspect of pancreatic cancer is very encouraging. These results illustrate the potential of Tumor Treating Fields therapy concomitant with gemcitabine and nab-paclitaxel to become a standard of care for unresectable, locally advanced pancreatic cancer.”

The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields.

“Most people with pancreatic cancer are diagnosed with advanced disease, which is very difficult to treat and only about 1 in 10 people are alive five years after diagnosis,” said Nicolas Leupin, MD, PhD, Chief Medical Officer, Novocure. “The results shared today at ASCO and in the Journal of Clinical Oncology demonstrate that Tumor Treating Fields therapy improved overall survival and pain-free survival in unresectable, locally advanced pancreatic cancer. We plan to submit these data to the FDA in the second half of 2025 to support a premarket approval for Tumor Treating Fields therapy.”

Results from PANOVA-3

In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement [hazard ratio (HR) 0.82; p=0.039 (N=571)].

Exhibit 99.1

TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints including the one-year survival rate and pain-free survival. Pancreatic cancer can cause significant pain as the disease progresses and managing pain is a key clinical challenge.

•The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group with 68.1% [95% CI: 62.0–73.5] compared to those who received gemcitabine and nab-paclitaxel alone, 60.2% [95% CI: 54.2–65.7], p=0.029.

•Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months [95% CI: 10.3–22.8] compared to a median 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone [95% CI: 7.4–12.7]; HR 0.74 [95% CI: 0.56–0.97], p=0.027. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until an increase of 20 or more points was reported by patients on a visual scale for pain or until death.

Quality of life was also measured as a secondary endpoint. Analyses were performed for all patients using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the pancreatic cancer specific PAN26 addendum. Deterioration-free survival in global health status, pain and digestive problems were significantly improved in patients receiving TTFields therapy concomitant with gemcitabine and nab-paclitaxel compared to the gemcitabine and nab-paclitaxel alone group. Full analysis of the quality of life results in PANOVA-3 will be shared at a future scientific conference.

There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms.

TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs.

Data Presentation & Publication Details

The PANOVA-3 data, (LBA 3500) Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC), will be presented today by Dr. Picozzi in Hall D1 during the 3:00 – 6:00 p.m. Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary oral session.

The Phase 3 PANOVA-3 publication in the Journal of Clinical Oncology, Tumor Treating Fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase 3 PANOVA-3 study, will be available online at https://ascopubs.org/doi/10.1200/JCO-25-00746.

Novocure Investor Event

Novocure will host an investor event featuring Dr. Picozzi and Novocure leadership after the oral presentation. Event details and a link to a live webcast of the event are available on the investor relations page of www.novocure.com. For more information or to request in-person attendance, please contact Novocure investor relations at investorinfo@novocure.com.

Exhibit 99.1

Regulatory & Ongoing Clinical Study of TTFields for Pancreatic Cancer

Novocure plans to file for regulatory approval for use of TTFields therapy in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3 in the U.S. in the second half of 2025. The company also plans to file for regulatory approval in EU, Japan and other key markets.

Novocure continues to follow patients in its Phase 2 PANOVA-4 trial exploring the use of TTFields therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment with data anticipated in the first half of 2026.

About PANOVA-3

PANOVA-3 is an international, prospective, randomized, open-label, controlled Phase 3 clinical trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields) therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment for locally advanced pancreatic adenocarcinoma. Patients were randomized to receive either TTFields therapy concomitant with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone.

The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity.

The PANOVA-3 trial enrolled 571 patients who were randomized 1:1 and followed for a minimum of 18 months.

About PANOVA-4

PANOVA-4 is an international, multi-center, Phase 2 clinical trial designed to test the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. The primary endpoint is disease control rate. Secondary endpoints include overall survival, progression-free survival, one-year survival rate, objective response rate, progression-free survival at six months, duration of response, and toxicity. The study is designed to enroll 76 patients and enrollment is complete.

About Pancreatic Cancer

Pancreatic cancer is one of the most lethal cancers and is the third most frequent cause of death from cancer in the U.S.[i] While overall cancer incidence and death rates are remaining stable or declining, the incidence and death rates for pancreatic cancer are increasing.[ii] It is estimated that approximately 67,000 patients are diagnosed with pancreatic cancer each year in the U.S.[iii] Pancreatic cancer has a five-year relative survival rate of just 13%.[iv]

Physicians use different combinations of surgery, radiation and pharmacological therapies to treat pancreatic cancer, depending on the stage of the disease. For patients with locally advanced pancreatic cancer involving encasement of arteries but no extra-pancreatic disease, the standard of care is surgery followed by chemotherapy with or without radiation. Unfortunately, most locally advanced cases are diagnosed when the cancer is no longer operable, generally leaving chemotherapy with or without radiation as the only treatment option.

About Tumor Treating Fields

Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in

Exhibit 99.1

approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors.

To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.

Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Investors: Ingrid Goldberg investorinfo@novocure.com

Media: Catherine Falcetti media@novocure.com

[i] American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025

[ii] American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025

Exhibit 99.1

[iii] American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025

[iv] American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025

panova3oralpresentationf

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3: Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for locally advanced pancreatic adenocarcinoma (LA-PAC) Vincent Picozzi, Hani Babiker, Sreenivasa Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, Javier Gallego, Andrea Bullock, Hao Chunyi, Lucjan Wyrwicz, Arsen Osipov, Christelle de la Fouchardiere, Tomislav Dragovich, Woojin Lee, Kynan Feeney, Philip A. Philip, Makoto Ueno, Eric Van Cutsem, Thomas Seufferlein, Teresa Macarulla on behalf of the PANOVA-3 study investigators Dr Vincent Picozzi 1Virginia Mason Medical Center, Seattle, Washington, USA; 2Mayo Clinic, Jacksonville, Florida, USA; 3The Cancer & Hematology Centers, Michigan, USA; 4Palacky University and University Hospital Olomouc, Olomouc, Czech Republic; 5University of Kansas Medical Center, Kansas City, Kansas, USA; 6Changhai Hospital, Shanghai, China; 7General University Hospital Elche, Elche, Spain; 8Harvard Medical School, Harvard University, Boston, Massachusetts, USA; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 9Beijing Cancer Hospital, Beijing, China; 10National Institute of Oncology; Maria Sklodowska Curie National Cancer Research Institute, Warsaw, Poland; 11Cedars-Sinai Medical Center, Los Angeles, CA; 12Centre Léon Bérard, Lyon, France; 13Baptist MD Anderson Cancer Center, Jacksonville, Florida, USA; 14National Cancer Center, Goyang, Republic of Korea; 15St John of God Murdoch Hospital, Murdoch, Western Australia, Australia; 16Wayne State University/Henry Ford Hospital, Jackson, Michigan, USA; 17Kanagawa Cancer Center, Yokohama, Japan; 18University Hospitals Gasthuisberg and University of Leuven (KUL), Leuven, Belgium; 19University Hospital, Ulm, Germany; 20Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain Exhibit 99.2

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Key Takeaway Points/Conclusions 2 Survival benefit for patients is supported by significantly improved QoL and pain-free survival* compared with GnP alone The only frequently reported TTFields toxicity was localized skin reactions *as the time to a ≥ 20-point increase from baseline on a patient-reported visual analogue scale for pain or death. GnP, gemcitabine/nab-paclitaxel; LA-PAC, locally advanced pancreatic adenocarcinoma; OS, overall survival; TTFields, Tumor Treating Fields. PANOVA-3 is the first phase 3 trial in patients with unresectable LA-PAC to show an OS benefit over gemcitabine/nab-paclitaxel PANOVA-3 establishes TTFields with GnP as a potential new standard paradigm for unresectable LA-PAC Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. LA- PAC, a high unmet need 3 • Pancreatic adenocarcinoma remains a high unmet need with a modest 5-year survival rate of 8%1,2 ➢About 30–35% of patients present with LA-PAC* and only 10–15% of them will be eligible for potentially curative surgery3 ➢The remaining patients are incurable and will experience debilitating symptoms, especially pain • The current SOC for unresectable LA-PAC is chemotherapy (GnP, FOLFIRINOX, NALIRIFOX) ± radiation4-6 • While most trials of novel agents have focused on patients with metastatic disease,7-9 recent studies in patients with LA-PAC have failed to demonstrate overall survival benefit over the current SOC10,11 *LA-PAC was defined as histological/cytological diagnosis of de novo adenocarcinoma of the pancreas, which was deemed unresectable, locally advanced by investigator. GnP, gemcitabine/nab-paclitaxel; FOLFIRINOX, 5-FU/leucovorin, irinotecan, and oxaliplatin; LA-PAC, locally advanced pancreatic adenocarcinoma; NALFIRINOX, liposomal irinotecan, oxaliplatin, 5-FU/leucovorin, SOC, standard of care; References: 1. National Cancer Institute 2025; 2. American Cancer Society. Cancer Facts & Figures 2025. 3. Park W, et al. JAMA. 2021;326(9):851-862; 4. Conroy T, et al. Ann Oncol 2023;34(11):987-1002; 5. National Comprehensive Cancer Network (NCCN). NCC Guidelines in Oncology. Pancreatic Adenocarcinoma. 2024; 6. Wainberg ZA, et al. Lancet 2023 Oct 7;402(10409):1272-1281; 7. Picozzi VJ, et al. J Clin Oncol 43, 2025 (suppl 4; abstr 673); 8. Hu ZI, et al. Nat Rev Gastroenterol Hepatol 2024; 21 (1):7-24; 1961-703; 9. Anderson EM, et al. Cancers (Basel)2021; 13(21):5510; 10. De La Fouchardiere C, et al. J Clin Oncol 2024;42(9):105-66; 7); 11. Hammel P et al. JAMA 2016;315(17):1844-53. Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. TTFields therapy 4 • TTFields are electric fields that disrupt processes critical for cancer cell division1-3 and may trigger an enhanced antitumor immune response • TTFields therapy is delivered noninvasively to the tumor site via a portable device that consists of a field generator and arrays placed on the skin4,5 • TTFields concomitant with systemic therapy is approved in the US and Europe for GBM, MPM, and metastatic NSCLC,6,7 and in Japan for GBM • TTFields with gemcitabine ± nab-paclitaxel was feasible and well tolerated in patients with advanced pancreatic adenocarcinoma in the phase 2 PANOVA pilot trial8 GBM, glioblastoma; MPM, malignant pleural mesothelioma; NSCLC, non-small cell lung cancer; TTFields, Tumor Treating Fields. 1. Kirson ED et al. Cancer Res. 2004;64(9):3288-3295. 2. Mun EJ et al. Clin Cancer Res. 2018;24(2):266-275. 3. Voloshin T et al. Cancers (Basel). 2020;12(10):3016; 4. Optune. Instructions for Use. Novocure; January 2019. 5. NovoTTF-100L. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021; 6. Optune Lua® for Non-Small Cell Lung Cancer (NSCLC) – Patient Information and Operation Manual. Available at: https://assets.novocure.biz/optunelua/2024- 10/Optune%20Lua%20NSCLC%20ITE%20PIOM_v%2008.pdf; 7. Optune Gio®– Instructions for Use. Available at: https://www.optunegio.com/instructions-for-use; 8. Rivera F et al. Pancreatology 2017; 19(1):64-72. Actor portrayal Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3 study design 5 R 1:1 Gemcitabine 1000 mg/m2† Nab-paclitaxel 125 mg/m2† TTFields therapy* Gemcitabine 1000 mg/m2† Nab-paclitaxel 125 mg/m2† Follow-up Q4W (CT scan Q8W) Follow-up Q4W (CT scan Q8W) Monthly survival follow-up after local progression N = 571 Patients with locally advanced pancreatic adenocarcinoma Stratified by ECOG PS & region *150 kHz, 18h/day; †On days 1, 8, and 15 of each 28-day cycle; ‡ US, Mexico, Brazil, Canada; Spain, Hungary, Czech Republic, France, Poland, Germany, Austria, Switzerland, Italy, Israel, Belgium, Croatia; China, South Korea, Australia and Hong Kong; CT, computer tomography; ECOG PS, Eastern Cooperative Oncology Group Performance Status; R, randomization; TTFields, Tumor Treating Fields; Q4W, every 4 weeks; Q8W, every 8 weeks. Key inclusion criteria: • Adults ≥18 years • Previously untreated, biopsy confirmed disease • Life expectancy ≥3 months • ECOG PS 0-2 Key exclusion criteria: • Prior palliative treatment to the tumor • Implanted electronic medical device in torso • Known allergies to medical adhesives, hydrogel or chemotherapies Study sites: 198 across 20 countries (North and South America, Europe, Asia)‡ Enrollment: March 2018 – March 2023 Data cut-off: October 16, 2024 Registration number: NCT03377491 Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3: Endpoints and statistical analyses 6 *Compared using one-sided t-test after the directionality of the effect was established; †Compared using one-sided Fisher’s exact test with α=0.05. GnP, gemcitabine/nab-paclitaxel; ITT, intent-to-treat population; KM, Kaplan-Meier; mITT, modified intent-to-treat population; ORR, overall response rate; OS, overall survival; PFS, progression-free survival, TTFields, Tumor Treating Fields. • Primary and secondary endpoints were investigated in the ITT and mITT populations (= all patients treated with ≥1 full cycle of GnP and/or ≥28 days with TTFields) • OS was analyzed using the KM method, comparison of KM curves was done using two-sided log-rank test stratified by region • Pain-free survival: time from randomization until ≥20-point increase from baseline in a patient- reported visual analogue scale for pain or death Secondary endpoints (selected) • PFS (powered secondary endpoint) • Local PFS • Pain-free survival • 1-yr survival rate* • ORR † • Safety Post-hoc analysis • Distant PFS Primary endpoint • OS Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Patient disposition 7 † One full GnP cycle is defined as 3 complete administrations per cycle. GnP, gemcitabine/nab-paclitaxel; ITT, intent-to-treat population; mITT, modified intent-to-treat population; TTFields, Tumor Treating Fields.. Screened N=753 Randomized N=571 TTFields + GnP n=285 GnP n=286 Treated TTFields + GnP n=277 Max. 7 days from randomization Treated GnP n=270 Max. 7 days from randomization Started TTFields + GnP n=274 Started GnP n=273 Treated for ≥28 days with TTFields + ≥1 full cycle of GnP† n=198 Treated with ≥1 full cycle of GnP† n=207 ITT excluded from mITT n=87 Randomized, not treated: n=8 Not treated with TTFields: n=3* ITT excluded from mITT n=79 Randomized, not treated: n= 6 ITT mITT Safety • ITT included all randomized patients regardless of treatment received; mITT included all patients who received at least one complete cycle of treatment (≥28 days with TTFields + ≥1 full cycle of GnP) • The number of discontinuations in both arms during the first 28 days after inclusion was mostly related to disease progression or patients’ decision *3 patients moved to SOC arm Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3: Patients characteristics 8 CA19-9, carbohydrate antigen 19-9; ECOG PS, Eastern Cooperation Oncology Group performance status; GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor Treating Fields. TTFields + GnP (n=285) GnP (n=286) Overall (n=571) Median age (range) Years 67 (31, 90) 67.5 (40, 88) 67 (31, 90) Gender, n (%) Male 147 (51.6) 125 (43.7) 272 (47.6) Female 138 (48.4) 161 (56.3) 299 (52.4) Race, n (%) American Indian or Alaska Native 9 (3.2) 4 (1.4) 13 (2.3) Asian 44 (15.4) 44 (15.4) 88 (15.4) Black or African American 16 (5.6) 14 (4.9) 30 (5.3) White 202 (70.9) 204 (71.3) 406 (71.1) Other 3 (1.1) 5 (1.7) 8 (1.4) Not Reported 11 (3.9) 15 (5.2) 26 (4.6) ECOG PS, n (%) 0 109 (38.2) 111 (38.8) 220 (38.5) 1 166 (58.2) 163 (57.0) 329 (57.6) 2 10 (3.5) 12 (4.2) 22 (3.9) CA 19-9, n (%) Normal (≤37 U/mL) 48 (16.8) 44 (15.4) 92 (16.1) Elevated (38–1,000 U/mL) 140 (49.1) 152 (53.1) 292 (51.1) High (>1,000 U/mL) 88 (30.9) 79 (27.6) 167 (29.2) Untested 9 (3.2) 11 (3.8) 20 (3.5) • Characteristics were generally well balanced between the 2 study arms ▪ More females than males in the gemcitabine/ nab-paclitaxel arm • High CA 19-9 values may be indicative of very advanced disease Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3: Treatment characteristics 9 GnP, gemcitabine/nab-paclitaxel; NA, not applicable; TTFields, Tumor Treating Fields. • Duration of exposure to gemcitabine and nab-paclitaxel was similar in the study arms • The distribution of salvage therapies was balanced between the study arms Duration of exposure – ITT population TTFields + GnP (n=285) GnP (n=286) Gemcitabine Median cycles received, n (range) 6.0 (1.0, 57.0) 6.0 (1.0, 30.0) Median duration of exposure, weeks (range) 24.1 (0.1, 232.4) 22.1 (0.1, 134.1) Nab-paclitaxel Median cycles received, n (range) 6.0 (1.0, 57.0) 5.0 (1.0, 30.0) Median duration of exposure, weeks (range) 23.0 (0.1, 232.4) 21.4 (0.1, 134.1) TTFields Median daily device usage, % (range) 62.1 (0, 99.0) NA Median duration of exposure, weeks (range) 27.6 (0.1, 234.4) NA Median follow-up, months (range) 13.5 (0.03, 55.2) 12.9 (0.03, 50.1) Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Primary endpoint: overall survival ITT TTFields + GnP GnP P-value Median OS (95% CI) Events 16.2 (15.0, 18.0) 201 14.2 (12.8, 15.4) 230 0.039 HR = 0.82 (95% CI: 0.68, 0.99) 1-year survival rate, Median (95% CI) 68.1 (62.0, 73.5) 60.2 (54.2, 65.7) 0.029 10 ITT Population CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; mITT, modified intent-to-treat population; OS, overall survival; TTFields, Tumor Treating Fields. 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 2412 30186 14285 50166224 26104 9286 41164 1698228 P ro b a b il it y o f o v e ra ll s u rv iv a l MonthsNumber at risk TTFields + GnP GnP GnP TTFields + GnP + Censored 36 mITT TTFields + GnP GnP P-value Median OS (95% CI) Events 18.3 (16.1, 20.0) 151 15.1 (13.4, 17.0) 169 0.023 HR = 0.77 (95% CI: 0.62, 0.97) 1-year survival rate, Median (95% CI) 75.1 (68.3, 80.6) 65.9 (59.0, 72.0) 0.022 Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Secondary endpoints: PFS and local PFS 11 PFS – ITT population Local PFS* – ITT population *Progressive disease per revised RECIST version 1.1 in the absence of distant metastasis, including non-regional lymph node metastasis, and abdominal metastases. CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; PFS, progression-free survival; TTFields, Tumor Treating Fields. 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 2418126 9 6 285 3079153 286 1750133 Number at risk TTFields + GnP GnP P ro b a b il it y o f p ro g re s s io n -f re e s u rv iv a l Months + Censored GnP TTFields + GnP 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 2418126 9285 3690162 8286 2056139 Number at risk TTFields + GnP GnP P ro b a b il it y o f lo c a l p ro g re s s io n -f re e s u rv iv a l Months GnP + Censored TTFields + GnP TTFields + GnP GnP P-value Median PFS (95% CI) Events 10.6 (9.2, 12.2) 176 9.3 (7.6, 11.1) 162 0.137 HR = 0.85 (95% CI: 0.68, 1.05) 1-year PFS rate, Median (95% CI) 43.9 (36.9, 50.6) 34.1 (27.1, 41.2) 0.026 TTFields + GnP GnP P-value Median local PFS (95% CI) Events 12.5 (10.7, 14.5) 155 10.4 (9.1, 11.8) 139 0.151 HR = 0.84 (95% CI: 0.67, 1.06) 1-year local PFS rate, Median (95% CI) 51.9 (44.8, 58.6) 41.8 (34.2, 49.2) 0.027 Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Post-hoc analysis: Distant PFS* 12 *Defined as progressive disease per revised RECIST version 1.1 in the absence of local progression. CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; PFS, progression-free survival; TTFields, Tumor Treating Fields. ITT TTFields + GnP GnP P-value Median distant PFS (95% CI) Events 13.9 (12.2, 16.8) 113 11.5 (10.4, 12.9) 119 0.022 HR = 0.74 (95% CI: 0.57, 0.96) 1-year distant PFS rate, Median (95% CI) 58.5 (50.7, 65.4) 47.6 (39.6, 55.2) 0.024 ITT population1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 2418126 11285 3386164 6286 1955138 Number at risk TTFields + GnP GnP Months + Censored GnP TTFields + GnP P ro b a b il it y o f d is ta n t P F S Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Secondary endpoint: pain-free survival* 13 CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; TTFields, Tumor Treating Fields; VAS, visual analogue scale. *Pain-free survival was defined as the time to a ≥ 20-point increase from baseline on a patient-reported visual analogue scale (VAS) for pain or death ITT population 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 12 186 285 758122 25 286 430 1298 TTFields + GnP GnP + Censored Number at risk TTFields + GnP GnP P ro b a b il it y o f p a in -f re e s u rv iv a l Months 24 ITT TTFields + GnP GnP P-value Median pain-free survival (95% CI) Events 15.2 (10.3, 22.8) 102 9.1 (7.4, 12.7) 110 0.027 HR = 0.74 (95% CI: 0.56, 0.97) 1-year pain-free survival rate, Median (95% CI) 54.1 (46.2, 61.3) 45.1 (36.8, 53.0) 0.056 Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. 14 *Defined as the first time-point a patient experienced a deterioration of ≥10 points in the respective QoL scale or death. GnP, gemcitabine/nab-paclitaxel; QoL, quality of life; TTFields; Tumor Treating Fields. ITT TTFields + GnP GnP P-value Median time to deterioration* (95% CI) Events 7.1 (5.7, 9.4) 146 5.7 (4.1, 7.4) 160 0.023 HR = 0.77 (95% CI: 0.61, 0.97) 1-year deterioration-free rate, median (95% CI) 33.3 (26.1, 40.8) 23.3 (16.6, 30.7) 0.0414 • QoL analyses were performed in all patients using the EORTC QLQ C30 questionnaire with the pancreatic cancer-specific PAN26 addendum • Deterioration-free survival in global health status, pain and digestive problems were significantly improved in patients receiving TTFields Therapy • Full QoL data will be presented in the near future + Censored 0 12 186 Time to 10-point deterioration including death (months) 24 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 P ro b a b il it y o f b e in g d e te ri o ra ti o n f re e TTFields + GnP GnP 285 23888 11 286 219 760 Number at risk TTFields + GnP GnP Secondary endpoint: Quality of Life Global Health Status Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Safety summary 15 AE, adverse event; GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor Treating Fields. 1. Von Hoff DD, et al. NEJM 2013;369(18):1691-703. • Rates of AEs were similar between arms • Toxicity profile as expected for treatment with gemcitabine/nab-paclitaxel overall1 • Higher number of skin AEs seen in the TTFields arm AE, n (%) TTFields + GnP (N=274) GnP (N=273) All grades Grade ≥3 All grades Grade ≥3 Serious AE 147 (53.6) 143 (52.2) 131 (48.0) 130 (47.6) AE leading to device discontinuation 23 (8.4) NA AE leading to chemotherapy discontinuation 47 (17.2) 43 (15.8) AE leading to death 17 (6.2) 16 (5.9) AEs occurring in ≥20% of patients overall, n (%) TTFields + GnP (N=274) GnP (N=273) All grades Grade ≥3 All grades Grade ≥3 Any AE 268 (97.8) 243 (88.7) 270 (89.9) 230 (84.2) Neutropenia 172 (62.8) 131 (47.8) 180 (65.9) 130 (47.6) Fatigue 165 (60.2) 29 (10.6) 148 (54.2) 21 (7.7) Anemia 161 (58.8) 60 (21.9) 158 (57.9) 61 (22.3) Thrombocytopenia 122 (44.5) 39 (14.2) 133 (48.7) 32 (11.7) Diarrhea 119 (43.4) 11 (4.0) 125 (45.8) 15 (5.5) Neuropathy peripheral 112 (40.9) 20 (7.3) 81 (29.7) 18 (6.6) Nausea 107 (39.1) 11 (4.0) 121 (44.3) 7 (2.6) Edema peripheral 107 (39.1) 5 (1.8) 99 (36.3) 2 (0.7) Leukopenia 85 (31.0) 47 (17.2) 98 (35.9) 42 (15.4) Dermatitis 82 (29.9) 8 (2.9) 8 (2.9) 0 Vomiting 82 (29.9) 7 (2.6) 79 (28.9) 15 (5.5) Hepatic enzyme increased 75 (27.4) 35 (12.8) 72 (26.4) 24 (8.8) Pyrexia 74 (27.0) 6 (2.2) 64 (23.4) 2 (0.7) Abdominal pain 73 (26.6) 11 (4.0) 83 (30.4) 12 (4.4) Rash 71 (25.9) 5 (1.8) 23 (8.4) 1 (0.4) Alopecia 71 (25.9) 0 86 (31.5) 2 (0.7) Musculoskeletal pain 70 (25.5) 3 (1.3) 79 (28.9) 5 (1.8) Constipation 65 (23.7) 1 (0.4) 57 (20.9) 0 Hypokalemia 63 (23.0) 12 (4.4) 70 (25.6) 20 (7.3) Pruritus 61 (22.3) 0 23 (8.4) 0 Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. 16 Device-related AEs, n (%) TTFields + GnP (N=274) All grades Grade ≥3 Any AE 222 (81.0) 26 (9.5) Any serious AE 1 (0.4) 0 Any AE leading to TTFields discontinuation 23 (8.4) 7 (2.6) Any AE leading to death 0 0 AEs occurring in ≥2% of patients Dermatitis 76 (27.7) 8 (2.9) Rash 48 (17.5) 4 (1.5) Pruritus 41 (15.0) 0 Rash maculo-papular 33 (12.0) 3 (1.1) Erythema 29 (10.6) 0 Skin irritation 25 (9.1) 2 (0.7) Skin reaction 17 (6.2) 1 (0.4) Skin ulcer 14 (5.1) 1 (0.4) Blister 10 (3.6) 0 Fatigue 12 (4.4) 2 (0.7) Abdominal pain 9 (3.3) 0 Diarrhea 7 (2.6) 0 Skin injury 8 (2.9) 0 Thermal burn 6 (2.2) 0 AE, adverse event; GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor Treating Fields. Device-related adverse events • No new safety signals were observed • No deaths were attributed to TTFields • Skin AEs were the most common device-related AEs ▪ Majority were grade 1/2 and manageable with appropriate skin-care routines ▪ 7.7% of patients reported a grade 3 skin AE Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Key Takeaway Points/Conclusions 17 Survival benefit for patients is supported by significantly improved QoL and pain-free survival* compared with GnP alone The only frequently reported TTFields toxicity was localized skin reactions *as the time to a ≥ 20-point increase from baseline on a patient-reported visual analogue scale for pain or death. GnP, gemcitabine/nab-paclitaxel; LA-PAC, locally advanced pancreatic adenocarcinoma; OS, overall survival; TTFields, Tumor Treating Fields. PANOVA-3 is the first phase 3 trial in patients with unresectable LA-PAC to show an OS benefit over gemcitabine/nab-paclitaxel PANOVA-3 establishes TTFields with GnP as a potential new standard paradigm for unresectable LA-PAC Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open- Label, Pivotal Phase III PANOVA-3 Study ascopubs.org QR code here Check out the accompanying podcast, “TTFields in Locally Advanced Pancreatic Adenocarcinoma,” with Drs. Eileen M. O’Reilly and Peter Li, located on the online publication’s main page or at asco.org/podcasts. Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. 19 Special thank you to all participating patients, their families, and clinical research teams for your commitment and contributions. Acknowledgements Medical writing support for this presentation was provided by Chelsea Higgins, Janin Knop and Christine Mormont of Novocure and Christine el Jundi of Bioscript Group. We thank Prof. Daniel Von Hoff for his contributions to design, development of, and guidance on the trial. We thank Dr. Hani Babiker, chair of the P3 steering committee & co-first author for his unwavering support to this trial and to TTFields. This study was sponsored by Novocure. Editorial support funded by Novocure Thank you to all participating sites around the world Austria: Salzburg Uniklinik fur Innere Medizin, Landes-Krankenhaus Steyr, Medical University of Graz, Klinikum Klagenfurt am Wörthersee; Australia: Greenslopes Oncology, Westmead Hospital, Sydney Adventist Hospital, St. John of God Murdoch Hospital, Monash Health; Belgium: University of Leuven, Research UZ/KU Leuven, Clinique Universutaire Saint Luc - Institut Roi Albert; Brazil: Instituto Ribeiraopretano de Combate ao Cancer, Instituto Brasileiro de Controle do Cancer (IBCC), Hospital de Clínicas de Porto Alegre, COI, Ynova Pesquisa Clinica, Hospital de Caridade de Ijui (HCI), Centro de Pesquisa Clínica Multidisciplinar da Santa Casa de Porto Alegre, Hospital São Lucas da PUCRS, Oncoclinicas Rio de Janeiro S.A.’ Instituto D’Or de Pesquisa e Ensino – Matriz Rio de Janeiro, Instituto D’Or de Pesquisa e Ensino – Filial Salvador (Hospital São Rafael), Instituto D’Or de Pesquisa e Ensino; Canada: Centre Hospitalier Universitaire de Sherbrooke CIUSSS de l’Estrie – CHUS, London Health Science Center London Regional Cancer Program, Centre Hospitalier de l'Universite de Montreal- CHUM CIUSSS de l’Estrie – CHUS; People’s Republic of China: Beijing Cancer Hospital, Jilin Guowen Hospital, Henan Provincial People’s Hospital, Shanghai Changhai Hospital, Xingtai People’s Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xi'an Jiaotong University, Beijing University People's Hospital, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Shanxi Province Cancer Hospital, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Sun Yat- Sen Memorial Hospital of Sun Yat-Sen University, Guangdong Provincial People's Hospital, Bethune First Hospital of Jilin University, Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine, Linyi Cancer Hospital, Harbin Medical University Cancer Hospital, Beijing Union Medical College Hospital; Croatia: UHC Zagreb; Czech Republic: Olomouc Fakultni Nemocnice, Nemocnice Na Bulovce, General University Hospital in Prague, Nemocnice Novy Jicin, Masaryk Institute of Oncology; France: Institut de Cancérologie de l’Ouest (ICO), Hopital Saint-Antoine, Centre Léon Bérard, Hopital haut-Léveque CHU Bordeaux - Service d'Hépato- Gastroentérologie et d'Oncologie digestive, Strasbourg Oncologie Liberale, Hospital Group Bretagne Sud, Centre Armoricain d'Oncologie – CARIO, Centre de Lutte Contre le Cancer (CLCC) - Centre Paul Strauss; Germany: Klinik München Bogenhausen, Universitätsklinikum Ulm, Carl-von-Basedow-Klinikum Saalekreis, Medizinische Hochschule Hannover, Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Bonifatius Hospital Hematology and Oncology Lingen, Klinikum Chemnitz gGmbH; Hong Kong: Queen Mary Hospital; Hungary: Bacs-Kiskun County Teaching Hospital, Jasz-Nagykun-Szolnok Megyei Hetenyi Geza, National Institute of Oncology, Tolna County Balassa Janos Hospital, Békés Megyei Pándy Kálmán Kórháza Megyei Onkológiai Központja; Israel: Haifa Rambam Medical Center, Tel Aviv Sourasky Medical Center, Hadassah Medical Center, Rabin Medical Center, Sheba Pancreatic Cancer Center; Italy:Università Campus Bio-Medico, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Ospedale Civile Ss. Antonio e Biagio e Cesare Arrigo, Ospedale San Giovanni, Azienda Ospedaliero-Universitaria Careggi; Mexico: Accelerium Clinical Research, Centro Potosino de Investigación Médica, Mediadvance Clinical, Centro de Investigación Médica Aguascalientes (CIMA), FAICIC Clinical Research, Clinstile S.A de C.V., Centro de Estudios de Alta Especialidad de Sinaloa, Phylasis Clinicas Research, Hospitales Star Medica, PCR Toluca Corporativo Hospital Satelite, Clinica Integral Internacional de Oncologia, Hospital Angeles - Centro Medico del Potosi, Practice of Centro Hemato Oncologico Privado, Hospital Universitario "Dr. Jose Eleuterio Gonzalez“; Poland: M.Sklodowska-Curie Inst.of Oncol., Klinika Onkologii Uniwersytetu Medyczneg, Mrukmed Medical Center, Uniwersytecki Szpital Kliniczny we Wrocławiu, Oncology and Radiotherapy Clinic University Clinical Center Non-Invasive Medicine Center; South Korea: Chonnam National University Hwasun Hospital, Dong-A University Hospital, Gachon University Gil Hospital, Inha University Hospital, Keimyung University, Dongsan hospital, Korea University Guro Hospital, National Cancer Center, Samsung Medical Center, Seoul National University Bundang Hospital, The Catholic University of Korea, Seoul St. Mary's Hospital, Severance Hospital, Ajou University Hospital, CHA Bundang Medical Center; Spain: Vall d'Hebron Barcelona, Madrid, HM Hospitales CIOCC, Instituto Oncologico Dr. Rosell, Hospital Universitario Ramon Y Cajal Carretera de Colmenar Viejo, Hospital Regional Universitario de Málaga, Marqués de Valdecilla University Hospital, Elche Hospital General Universitario, Inst. Valenciano de Oncologia, Pamplona Clinica Universidad de Navarra,; Switzerland: Fribourg Hôpital, Winterthur Kantonsspital; USA: Tennessee Oncology, Cedars Sinai, Ochsner Clinic Foundation, Associated Neurologists of Southern Connecticut, University of Minnesota, The University of Arizona Cancer Center, Texas Oncology, Comprehensive Cancer Center of Nevada, Karmanos Cancer Center, Norton Cancer Institute, Beth Israel Deaconess Medical Center (BIDMC), Erlanger Health System, West Virginia University, Banner MD Anderson Cancer Center, Seattle Cancer Care Alliance, Pacific Cancer Medical Center, Virginia Mason Medical Center, Novant Health Oncology Specialists, HCA Midwest Division of Sarah Cannon Research Institute, Laura and Issac Perimutter Cancer Center at NYU Langone, Mount Sinai Comprehensive Cancer Center (MSCCC), Vita Medical Associates, Loyola University Chicago, University of Kansas Cancer Center (KUCC), Boca Raton Clinical Research Medical Center, Florida Hospital Tampa, Dignity Health Cancer Institute, Florida Cancer Specialists, Florida Cancer Specialists, Renown Regional Medical Center, Piedmont Cancer Institute (PCI), Nebraska Methodist Hospital, Geisinger Medical Center, North Shore University Health, University of Maryland Comprehensive Cancer Center, University of Oklahoma Health Sciences Center, Arizona Oncology Associates, Oncology and Hematology Associates of Southwest Virginia, Texas Oncology – Bedford, Texas Oncology – Tyler, Texas Oncology - El Paso Cancer, Baylor, Scott and White Medical Center, Cancer & Hematology Centers of Western Michigan, Florida Hospital Cancer Institute, Houston Methodist Cancer Center and Institute of Academic Medicine, Cotton O’Neil Cancer Center Stormont Vail Health Care, Illinois Cancer Specialist, Texas Oncology - Beaumont Mamie, Maryland Oncology Hematology, Willamette Valley Cancer Institution, NY Presbyterian Queens, Infirmary Health, White Plains Hospital, Vista Oncology Group, Sutter Institute for Medical Research, Rush University Medical Center, Methodist Richardson Cancer Center, UMass Memorial Hospital, Lynn Cancer Institute, Boca Raton Regional Hospital, Grandview Health, General Physician Cancer Care – Williamsville, Hematology Oncology Central Maine Medical Center (CMMC), Cancer Specialist of North Florida, Providence Medical Foundation, Gabrail Cancer Center Research, Toledo Clinic Cancer Center, OptumCare, Tennessee Cancer Specialists, Princeton Radiation Oncology (Regional Cancer Care Associates LLC), Bassett Cancer Institute, Ridley Tree Cancer Center, Mayo Clinic Jacksonville, St. Elizabeth Healthcare, St. Helena Healthcare - Martin O'Neil Cancer Center Scan to access JCO publication Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Array Layouts 21 A) Epigastric-centered with the superior discs row at the level of the xiphoid B) Left hypochondriac-shifted to the left with the superior discs row at the level of the xiphoid C) Right hypochondriac-shifted to the right with the superior discs row at the level of the xiphoid D) Umbilical- centered with the superior discs row at the inferior border of the 10th costal cartilage Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Array Layouts – continued 22 E) Left lumbar-shifted to the left with the superior discs row at the inferior the 10th costal cartilage F) Right lumbar-shifted to the right with the superior discs row at the inferior border of the 10th costal cartilage. G) Large epigastric- centered with the superior discs row at the level of the xiphoid H) Large umbilical- centered with the inferior discs row below the umbilicus Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Secondary Endpoints in the mITT population 23 mITT TTFields + GnP GnP P-value Median PFS (95% CI) Events 11.2 (9.4, 13.1) 136 10.7 (9.1, 11.5) 121 0.183 HR = 0.84 (95% CI: 0.66, 1.08) 1-year PFS rate, median (95% CI) 48.5 (40.5, 56.0) 38.7 (30.5, 46.8) 0.044 PFS Local PFS mITT TTFields + GnP GnP P-value Median local PFS (95% CI) Events 12.9 (11.3, 15.1) 117 11.5 (9.8, 13.1) 101 0.194 HR = 0.84 (0.64. 1.10) 1-year local PFS rate, median (95% CI) 51.9 (44.8, 58.6) 41.8 (34.2, 49.2) 0.027 mITT TTFields + GnP GnP P-value Median distant PFS (95% CI) Events 15.6 (13.1, 18.4) 81 12.2 (11.3, 13.7) 88 0.017 HR = 0.69 (95% CI: 0.51, 0.94) 1-year distant PFS rate, median (95% CI) 64.4 (55.7, 71.8) 52.6 (43.4, 60.9) 0.013 Distant PFS (post-hoc) mITT TTFields + GnP GnP P-value Median pain-free survival (95% CI) Events 16.6 (11.0, 29.9) 79 9.2 (7.6, 12.9) 86 0.019 HR = 0.69 (95% CI: 0.50, 0.94) 1-year pain-free survival rate, Median (95% CI) 56.8 (48.1, 64.7) 45.8 (36.6, 54.6) 0.040 Pain-free survival Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Overall response rate (ITT population) 24 TTFields + GnP (n=244) GnP (n=243) Best overall response, n (%) CR 3 (1.2) 0 PR 85 (34.8) 73 (30.0) SD 142 (58.2) 150 (61.7) PD ORR, % (95% CI) 14 (5.7) 36.1 (30.0, 42.4) 20 (8.2) 30.0 (24.3, 36.2) Mean difference in ORR, % (95% CI) 1-sided p-value 6.0 (−2.4, 14.4) 0.094 Resectability rate, % (95% CI) 7.0% (4.3, 10.6) 10.1% (6.9, 14.2) CI, confidence interval; CR, complete response; GnP, gemcitabine/nab-paclitaxel; ITT, intent-to-treat population; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; TTFields, Tumor Treating Fields • ORR and resectability rate were not significantly improved with concomitant TTFields therapy • Resectability rate was comparable to other trials in this population Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Salvage Therapies 25 Summary of Salvage Systemic Therapies TTFields + GnP (N=285) GnP (N=286) Number of Subjects Having Salvage Systemic Therapies 146 (51.2) 134 (46.9) Fluorouracil 92 (32.3) 78 (27.3) Irinotecan hydrocholide 85 (29.8) 69 (24.1) Folinic acid 75 (26.3) 61 (21.3) Oxaliplatin 57 (20.0) 42 (14.7) Radiotherapy 48 (16.8) 44 (15.4) Gemcitabine Hydrochloride 29 (10.2) 24 (8.4) Capecitabine 27 (9.5) 23 (8.0) Paclitaxel Albumin 22 (7.7) 11 (3.8) Gimeracil; Oteracil; Tegafur 9 (3.2) 5 (1.7) Investigational Antineoplastic Drugs 8 (2.8) 5 (1.7) Traditional Medicine 3 (1.1) 4 (1.4) Cisplatin 3 (1.1) 2 (0.7) Dr Vincent Picozzi

PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Limitations 26 • Investigator's assesment of CT scans for response determination • While protocol included a clear definition of resectability at baseline, there was no such guidance for follow up visits • Gender imbalance between both arms • High discontinuation rate within the first month in both arms • The median OS in the control arm is lower than in other phase 2 and 3 trials, albeit in line with RWE data • Open label trial Dr Vincent Picozzi

panova-3ascoinvestoreven

© 2025 Novocure GmbH 2 ` entering a new era with expanding oncology platform POSITIVE PHASE 3 DATA IN LOCALLY ADV. PANCREATIC CANCER POSITIVE PHASE 3 DATA IN BRAIN METS FROM NSCLC COMMERCIALLY LAUNCHED IN NSCLC ESTABLISHED FOOTPRINT IN GLIOBLASTOMA NSCLC, non-small cell lung cancer; mets, metastases.

© 2025 Novocure GmbH 3 agenda TTFields: A Multi-Indication Platform | Ashley Cordova Pancreatic Cancer Overview | Nicolas Leupin, M.D., Ph.D. PANOVA-3 Clinical Trial Results | Vincent Picozzi, M.D. Novocure Corporate Update | Ashley Cordova Q&A | Vincent Picozzi, M.D., Novocure Executive Team

© 2025 Novocure GmbH 6 TTFields: platform therapy with 4 positive phase 3 trials in cancers with significant unmet needs glioblastoma non-small cell lung cancer brain mets from NSCLC locally advanced pancreatic cancer >$600m Annual revenue1 >4,000 Patients on therapy2 H2 2025 Planned regulatory submission Commercially launching Positive top-line data announced Extends TTIP FDA approved & CE mark obtained Extends OSExtends OS H2 2025 Planned regulatory submission Positive data presented & published Extends OS Efficacy outcomes for the indications listed above are reflective of TTFields therapy use together with standard of care therapies. 1. Full year 2024; 2. As of March 31, 2025. FDA, U.S. Food & Drug Administration,; NSCLC, non-small cell lung cancer; OS, overall survival; TTIP, time to intracranial progression

© 2025 Novocure GmbH 8 pancreatic cancer cases are on the rise globally Global ASR Incidence and Predicted Rates and Case Numbers From 1990-20301 UNITED STATES • Annual pancreatic cancer incidence: 67,000 • Annual PANOVA-3 eligible patients: 16,000 Between 1990 and 2019, global trends in pancreatic cancer age-standardized rate (ASR) increased for both men and women.1 1. An H et al. Dig Dis Sci. 2024;69(7);2450-2461. GERMANY • Annual pancreatic cancer incidence: 20,000 • Annual PANOVA-3 eligible patients: 4,800 JAPAN • Annual pancreatic cancer incidence: 47,000 • Annual PANOVA-3 eligible patients: 11,000

© 2025 Novocure GmbH 9 PROGNOSIS1 • 67,000+ new cases diagnosed annually in the U.S. • 3rd leading cause of cancer-related death • 5-year survival rate of only 13% DIAGNOSIS • Limited nonspecific symptoms of early-stage disease • Most patients diagnosed at advanced stage • Systemic treatment options are extremely limited RESECTABILITY • <20% of patients are eligible for resection at diagnosis2 • Highly complex procedures • Vascular invasion makes many tumors unresectable challenges of treating pancreatic cancer 180° Tumor contact with artery/vein ≤180° Tumor contact with artery/vein >180° Tumor contact w/ artery/vein deformity or contour irregularity RESECTABLE UNRESECTABLE 1. American Cancer Society. https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html. Accessed May 28, 2025; 2. National Comprehensive Cancer Network ®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Pancreatic Adenocarcinoma. Version 3.2024. August 2, 2024.

© 2025 Novocure GmbH 10 evaluating the standard of care: comparable efficacy profiles with differing toxicity and dosing burden GEMCITABINE + NAB-PACLITAXEL FOLFIRINOX GUIDELINES1 TOXICITY TREATMENT REGIMEN NCCN Category 2A recommendation; ~50% utilization NCCN Category 2A recommendation; ~50% utilization Lower toxicity burden Higher toxicity burden with substantial GI-related impact; recommended only for patients with good performance status Weekly cycles: 2 drips, 30 mins each2 Biweekly cycles: 3 drips, 5.5 hours total + chemotherapy injection + 46-hour PICC or central line administered chemotherapy3 No randomized, head-to-head trial of FOLFIRINOX and GnP has been conducted in any disease stage GnP, gemcitabine and nab-paclitaxel. 1. National Comprehensive Cancer Network ®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Pancreatic Adenocarcinoma. Version 3.2024. August 2, 2024. 2. Von Hoff D et al N Engl J Med. 2013:369(18):1691-1703. 3. Conroy T et al. N Engl J Med. 2011:364(19);1817-1825

© 2025 Novocure GmbH 12 ASCO phase 3 PANOVA-3 trial results VINCENT PICOZZI, M.D. Director of Pancreatic & Biliary Duct Cancer Virginia Mason Franciscan Health Leads the largest single practice in pancreatic cancer in the nation and has an active clinical research program, both at Virginia Mason and through the American College of Surgeons Oncology Group Member and former chair of Pancreatic Cancer Action Network (PanCAN) Medical Advisory Board

PRESENTED BY: PANOVA-3: Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for locally advanced pancreatic adenocarcinoma (LA-PAC) Vincent Picozzi, Hani Babiker, Sreenivasa Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, Javier Gallego, Andrea Bullock, Hao Chunyi, Lucjan Wyrwicz, Arsen Osipov, Christelle de la Fouchardiere, Tomislav Dragovich, Woojin Lee, Kynan Feeney, Philip A. Philip, Makoto Ueno, Eric Van Cutsem, Thomas Seufferlein, Teresa Macarulla on behalf of the PANOVA-3 study investigators Dr Vincent Picozzi 1Virginia Mason Medical Center, Seattle, Washington, USA; 2Mayo Clinic, Jacksonville, Florida, USA; 3The Cancer & Hematology Centers, Michigan, USA; 4Palacky University and University Hospital Olomouc, Olomouc, Czech Republic; 5University of Kansas Medical Center, Kansas City, Kansas, USA; 6Changhai Hospital, Shanghai, China; 7General University Hospital Elche, Elche, Spain; 8Harvard Medical School, Harvard University, Boston, Massachusetts, USA; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 9Beijing Cancer Hospital, Beijing, China; 10National Institute of Oncology; Maria Sklodowska Curie National Cancer Research Institute, Warsaw, Poland; 11Cedars-Sinai Medical Center, Los Angeles, CA; 12Centre Léon Bérard, Lyon, France; 13Baptist MD Anderson Cancer Center, Jacksonville, Florida, USA; 14National Cancer Center, Goyang, Republic of Korea; 15St John of God Murdoch Hospital, Murdoch, Western Australia, Australia; 16Wayne State University/Henry Ford Hospital, Jackson, Michigan, USA; 17Kanagawa Cancer Center, Yokohama, Japan; 18University Hospitals Gasthuisberg and University of Leuven (KUL), Leuven, Belgium; 19University Hospital, Ulm, Germany; 20Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

PRESENTED BY: Key Takeaway Points/Conclusions 14 Survival benefit for patients is supported by significantly improved QoL and pain-free survival* compared with GnP alone Dr Vincent Picozzi The only frequently reported TTFields toxicity was localized skin reactions *as the time to a ≥ 20-point increase from baseline on a patient-reported visual analogue scale for pain or death. GnP, gemcitabine/nab-paclitaxel; LA-PAC, locally advanced pancreatic adenocarcinoma; OS, overall survival; TTFields, Tumor Treating Fields. PANOVA-3 is the first phase 3 trial in patients with unresectable LA-PAC to show an OS benefit over gemcitabine/nab-paclitaxel PANOVA-3 establishes TTFields with GnP as a potential new standard paradigm for unresectable LA-PAC

PRESENTED BY: LA- PAC, a high unmet need 15 • Pancreatic adenocarcinoma remains a high unmet need with a modest 5-year survival rate of 8%1,2 About 30–35% of patients present with LA-PAC* and only 10–15% of them will be eligible for potentially curative surgery3 The remaining patients are incurable and will experience debilitating symptoms, especially pain • The current SOC for unresectable LA-PAC is chemotherapy (GnP, FOLFIRINOX, NALIRIFOX) ± radiation4-6 • While most trials of novel agents have focused on patients with metastatic disease,7-9 recent studies in patients with LA-PAC have failed to demonstrate overall survival benefit over the current SOC10,11 Dr Vincent Picozzi *LA-PAC was defined as histological/cytological diagnosis of de novo adenocarcinoma of the pancreas, which was deemed unresectable, locally advanced by investigator. GnP, gemcitabine/nab-paclitaxel; FOLFIRINOX, 5-FU/leucovorin, irinotecan, and oxaliplatin; LA-PAC, locally advanced pancreatic adenocarcinoma; NALFIRINOX, liposomal irinotecan, oxaliplatin, 5-FU/leucovorin, SOC, standard of care; References: 1. National Cancer Institute 2025; 2. American Cancer Society. Cancer Facts & Figures 2025. 3. Park W, et al. JAMA. 2021;326(9):851-862; 4. Conroy T, et al. Ann Oncol 2023;34(11):987-1002; 5. National Comprehensive Cancer Network (NCCN). NCC Guidelines in Oncology. Pancreatic Adenocarcinoma. 2024; 6. Wainberg ZA, et al. Lancet 2023 Oct 7;402(10409):1272-1281; 7. Picozzi VJ, et al. J Clin Oncol 43, 2025 (suppl 4; abstr 673); 8. Hu ZI, et al. Nat Rev Gastroenterol Hepatol 2024; 21 (1):7-24; 1961-703; 9. Anderson EM, et al. Cancers (Basel)2021; 13(21):5510; 10. De La Fouchardiere C, et al. J Clin Oncol 2024;42(9):105-66; 7); 11. Hammel P et al. JAMA 2016;315(17):1844-53.

PRESENTED BY: TTFields therapy 16 • TTFields are electric fields that disrupt processes critical for cancer cell division1-3 and may trigger an enhanced antitumor immune response • TTFields therapy is delivered noninvasively to the tumor site via a portable device that consists of a field generator and arrays placed on the skin4,5 • TTFields concomitant with systemic therapy is approved in the US and Europe for GBM, MPM, and metastatic NSCLC,6,7 and in Japan for GBM • TTFields with gemcitabine ± nab-paclitaxel was feasible and well tolerated in patients with advanced pancreatic adenocarcinoma in the phase 2 PANOVA pilot trial8 Dr Vincent Picozzi GBM, glioblastoma; MPM, malignant pleural mesothelioma; NSCLC, non-small cell lung cancer; TTFields, Tumor Treating Fields. 1. Kirson ED et al. Cancer Res. 2004;64(9):3288-3295. 2. Mun EJ et al. Clin Cancer Res. 2018;24(2):266-275. 3. Voloshin T et al. Cancers (Basel). 2020;12(10):3016; 4. Optune. Instructions for Use. Novocure; January 2019. 5. NovoTTF-100L. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021; 6. Optune Lua® for Non-Small Cell Lung Cancer (NSCLC) – Patient Information and Operation Manual. Available at: https://assets.novocure.biz/optunelua/2024- 10/Optune%20Lua%20NSCLC%20ITE%20PIOM_v%2008.pdf; 7. Optune Gio®– Instructions for Use. Available at: https://www.optunegio.com/instructions-for-use; 8. Rivera F et al. Pancreatology 2017; 19(1):64-72. Actor portrayal

PRESENTED BY: PANOVA-3 study design 17 Dr Vincent Picozzi R 1:1 Gemcitabine 1000 mg/m2† Nab-paclitaxel 125 mg/m2† TTFields therapy* Gemcitabine 1000 mg/m2† Nab-paclitaxel 125 mg/m2† Follow-up Q4W (CT scan Q8W) Follow-up Q4W (CT scan Q8W) Monthly survival follow-up after local progression N = 571 Patients with locally advanced pancreatic adenocarcinoma Stratified by ECOG PS & region *150 kHz, 18h/day; †On days 1, 8, and 15 of each 28-day cycle; ‡ US, Mexico, Brazil, Canada; Spain, Hungary, Czech Republic, France, Poland, Germany, Austria, Switzerland, Italy, Israel, Belgium, Croatia; China, South Korea, Australia and Hong Kong; CT, computer tomography; ECOG PS, Eastern Cooperative Oncology Group Performance Status; R, randomization; TTFields, Tumor Treating Fields; Q4W, every 4 weeks; Q8W, every 8 weeks. Key inclusion criteria: • Adults ≥18 years • Previously untreated, biopsy confirmed disease • Life expectancy ≥3 months • ECOG PS 0-2 Key exclusion criteria: • Prior palliative treatment to the tumor • Implanted electronic medical device in torso • Known allergies to medical adhesives, hydrogel or chemotherapies Study sites: 198 across 20 countries (North and South America, Europe, Asia)‡ Enrollment: March 2018 – March 2023 Data cut-off: October 16, 2024 Registration number: NCT03377491

PRESENTED BY: PANOVA-3: Endpoints and statistical analyses 18 Dr Vincent Picozzi *Compared using one-sided t-test after the directionality of the effect was established; †Compared using one-sided Fisher’s exact test with α=0.05. GnP, gemcitabine/nab-paclitaxel; ITT, intent-to-treat population; KM, Kaplan-Meier; mITT, modified intent-to-treat population; ORR, overall response rate; OS, overall survival; PFS, progression-free survival, TTFields, Tumor Treating Fields. • Primary and secondary endpoints were investigated in the ITT and mITT populations (= all patients treated with ≥1 full cycle of GnP and/or ≥28 days with TTFields) • OS was analyzed using the KM method, comparison of KM curves was done using two-sided log-rank test stratified by region • Pain-free survival: time from randomization until ≥20-point increase from baseline in a patient- reported visual analogue scale for pain or death Secondary endpoints (selected) • PFS (powered secondary endpoint) • Local PFS • Pain-free survival • 1-yr survival rate* • ORR † • Safety Post-hoc analysis • Distant PFS Primary endpoint • OS

PRESENTED BY: Patient disposition 19 Dr Vincent Picozzi † One full GnP cycle is defined as 3 complete administrations per cycle. GnP, gemcitabine/nab-paclitaxel; ITT, intent-to-treat population; mITT, modified intent-to-treat population; TTFields, Tumor Treating Fields.. Screened N=753 Randomized N=571 TTFields + GnP n=285 GnP n=286 Treated TTFields + GnP n=277 Max. 7 days from randomization Treated GnP n=270 Max. 7 days from randomization Started TTFields + GnP n=274 Started GnP n=273 Treated for ≥28 days with TTFields + ≥1 full cycle of GnP† n=198 Treated with ≥1 full cycle of GnP† n=207 ITT excluded from mITT n=87 Randomized, not treated: n=8 Not treated with TTFields: n=3* ITT excluded from mITT n=79 Randomized, not treated: n= 6 ITT mITT Safety • ITT included all randomized patients regardless of treatment received; mITT included all patients who received at least one complete cycle of treatment (≥28 days with TTFields + ≥1 full cycle of GnP) • The number of discontinuations in both arms during the first 28 days after inclusion was mostly related to disease progression or patients’ decision *3 patients moved to SOC arm

PRESENTED BY: PANOVA-3: Patients characteristics 20 Dr Vincent Picozzi CA19-9, carbohydrate antigen 19-9; ECOG PS, Eastern Cooperation Oncology Group performance status; GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor Treating Fields. TTFields + GnP (n=285) GnP (n=286) Overall (n=571) Median age (range) Years 67 (31, 90) 67.5 (40, 88) 67 (31, 90) Gender, n (%) Male 147 (51.6) 125 (43.7) 272 (47.6) Female 138 (48.4) 161 (56.3) 299 (52.4) Race, n (%) American Indian or Alaska Native 9 (3.2) 4 (1.4) 13 (2.3) Asian 44 (15.4) 44 (15.4) 88 (15.4) Black or African American 16 (5.6) 14 (4.9) 30 (5.3) White 202 (70.9) 204 (71.3) 406 (71.1) Other 3 (1.1) 5 (1.7) 8 (1.4) Not Reported 11 (3.9) 15 (5.2) 26 (4.6) ECOG PS, n (%) 0 109 (38.2) 111 (38.8) 220 (38.5) 1 166 (58.2) 163 (57.0) 329 (57.6) 2 10 (3.5) 12 (4.2) 22 (3.9) CA 19-9, n (%) Normal (≤37 U/mL) 48 (16.8) 44 (15.4) 92 (16.1) Elevated (38–1,000 U/mL) 140 (49.1) 152 (53.1) 292 (51.1) High (>1,000 U/mL) 88 (30.9) 79 (27.6) 167 (29.2) U tested 9 (3.2) 11 (3.8) 20 (3.5) • Characteristics were generally well balanced between the 2 study arms  More females than males in the gemcitabine/ nab-paclitaxel arm • High CA 19-9 values may be indicative of very advanced disease

PRESENTED BY: PANOVA-3: Treatment characteristics 21 Dr Vincent Picozzi GnP, gemcitabine/nab-paclitaxel; NA, not applicable; TTFields, Tumor Treating Fields. • Duration of exposure to gemcitabine and nab- paclitaxel was similar in the study arms • The distribution of salvage therapies was balanced between the study arms Duration of exposure – ITT population TTFields + GnP (n=285) GnP (n=286) Gemcitabine Median cycles received, n (range) 6.0 (1.0, 57.0) 6.0 (1.0, 30.0) Median duration of exposure, weeks (range) 24.1 (0.1, 232.4) 22.1 (0.1, 134.1) Nab-paclitaxel Median cycles received, n (range) 6.0 (1.0, 57.0) 5.0 (1.0, 30.0) Median duration of exposure, weeks (range) 23.0 (0.1, 232.4) 21.4 (0.1, 134.1) TTFields Median daily device usage, % (range) 62.1 (0, 99.0) NA Median duration of exposure, weeks (range) 27.6 (0.1, 234.4) NA Median follow-up, months (range) 13.5 (0.03, 55.2) 12.9 (0.03, 50.1)

PRESENTED BY: Primary endpoint: overall survival Dr Vincent Picozzi ITT TTFields + GnP GnP P-value Median OS (95% CI) Events 16.2 (15.0, 18.0) 201 14.2 (12.8, 15.4) 230 0.039 HR = 0.82 (95% CI: 0.68, 0.99) 1-year survival rate, Median (95% CI) 68.1 (62.0, 73.5) 60.2 (54.2, 65.7) 0.029 22 ITT Population CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; mITT, modified intent-to-treat population; OS, overall survival; TTFields, Tumor Treating Fields. 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 2412 30186 14285 50166224 26104 9286 41164 1698228 Pr ob ab ili ty o f o ve ra ll su rv iv al MonthsNumber at risk TTFields + GnP GnP GnP TTFields + GnP + Censored 36 mITT TTFields + GnP GnP P-value Median OS (95% CI) Events 18.3 (16.1, 20.0) 151 15.1 (13.4, 17.0) 169 0.023 HR = 0.77 (95% CI: 0.62, 0.97) 1-year survival rate, Median (95% CI) 75.1 (68.3, 80.6) 65.9 (59.0, 72.0) 0.022

PRESENTED BY: Secondary endpoints: PFS and local PFS 23 Dr Vincent Picozzi PFS – ITT population Local PFS* – ITT population *Progressive disease per revised RECIST version 1.1 in the absence of distant metastasis, including non-regional lymph node metastasis, and abdominal metastases. CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; PFS, progression-free survival; TTFields, Tumor Treating Fields. 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 2418126 9 6 285 3079153 286 1750133 Number at risk TTFields + GnP GnP Pr ob ab ili ty o f pr og re ss io n- fr ee s ur vi va l Months + Censored GnP TTFields + GnP 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 2418126 9285 3690162 8286 2056139 Number at risk TTFields + GnP GnP Pr ob ab ili ty o f l oc al pr og re ss io n- fr ee s ur vi va l Months GnP + Censored TTFields + GnP TTFields + GnP GnP P-value Median PFS (95% CI) Events 10.6 (9.2, 12.2) 176 9.3 (7.6, 11.1) 162 0.137 HR = 0.85 (95% CI: 0.68, 1.05) 1-year PFS rate, Median (95% CI) 43.9 (36.9, 50.6) 34.1 (27.1, 41.2) 0.026 TTFields + GnP GnP P-value Median local PFS (95% CI) Events 12.5 (10.7, 14.5) 155 10.4 (9.1, 11.8) 139 0.151 HR = 0.84 (95% CI: 0.67, 1.06) 1-year local PFS rate, Median (95% CI) 51.9 (44.8, 58.6) 41.8 (34.2, 49.2) 0.027

PRESENTED BY: Post-hoc analysis: Distant PFS* 24 Dr Vincent Picozzi *Defined as progressive disease per revised RECIST version 1.1 in the absence of local progression. CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; PFS, progression-free survival; TTFields, Tumor Treating Fields. ITT TTFields + GnP GnP P-value Median distant PFS (95% CI) Events 13.9 (12.2, 16.8) 113 11.5 (10.4, 12.9) 119 0.022 HR = 0.74 (95% CI: 0.57, 0.96) 1-year distant PFS rate, Median (95% CI) 58.5 (50.7, 65.4) 47.6 (39.6, 55.2) 0.024 ITT population1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 2418126 11285 3386164 6286 1955138 Number at risk TTFields + GnP GnP Months + Censored GnP TTFields + GnP Pr ob ab ili ty o f d is ta nt P FS

PRESENTED BY: Secondary endpoint: pain-free survival* 25 Dr Vincent Picozzi CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; TTFields, Tumor Treating Fields; VAS, visual analogue scale. *Pain-free survival was defined as the time to a ≥ 20-point increase from baseline on a patient-reported visual analogue scale (VAS) for pain or death ITT population1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 12 186 285 758122 25 286 430 1298 TTFields + GnP GnP + Censored Number at risk TTFields + GnP GnP Pr ob ab ili ty o f p ai n- fr ee s ur vi va l Months 24 ITT TTFields + GnP GnP P-value Median pain-free survival (95% CI) Events 15.2 (10.3, 22.8) 102 9.1 (7.4, 12.7) 110 0.027 HR = 0.74 (95% CI: 0.56, 0.97) 1-year pain-free survival rate, Median (95% CI) 54.1 (46.2, 61.3) 45.1 (36.8, 53.0) 0.056

PRESENTED BY: 26 Dr Vincent Picozzi *Defined as the first time-point a patient experienced a deterioration of ≥10 points in the respective QoL scale or death. GnP, gemcitabine/nab-paclitaxel; QoL, quality of life; TTFields; Tumor Treating Fields. ITT TTFields + GnP GnP P-value Median time to deterioration* (95% CI) Events 7.1 (5.7, 9.4) 146 5.7 (4.1, 7.4) 160 0.023 HR = 0.77 (95% CI: 0.61, 0.97) 1-year deterioration-free rate, median (95% CI) 33.3 (26.1, 40.8) 23.3 (16.6, 30.7) 0.0414 • QoL analyses were performed in all patients using the EORTC QLQ C30 questionnaire with the pancreatic cancer-specific PAN26 addendum • Deterioration-free survival in global health status, pain and digestive problems were significantly improved in patients receiving TTFields Therapy • Full QoL data will be presented in the near future + Censored 0 12 186 Time to 10-point deterioration including death (months) 24 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Pr ob ab ili ty o f b ei ng d et er io ra tio n fr ee TTFields + GnP GnP 285 23888 11 286 219 760 Number at risk TTFields + GnP GnP Secondary endpoint: Quality of Life Global Health Status

PRESENTED BY: Safety summary 27 Dr Vincent Picozzi AE, adverse event; GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor Treating Fields. 1. Von Hoff DD, et al. NEJM 2013;369(18):1691-703. • Rates of AEs were similar between arms • Toxicity profile as expected for treatment with gemcitabine/nab-paclitaxel overall1 • Higher number of skin AEs seen in the TTFields arm AE, n (%) TTFields + GnP (N=274) GnP (N=273) All grades Grade ≥3 All grades Grade ≥3 Serious AE 147 (53.6) 143 (52.2) 131 (48.0) 130 (47.6) AE leading to device discontinuation 23 (8.4) NA AE leading to chemotherapy discontinuation 47 (17.2) 43 (15.8) AE leading to death 17 (6.2) 16 (5.9) AEs occurring in ≥20% of patients overall, n (%) TTFields + GnP (N=274) GnP (N=273) All grades Grade ≥3 All grades Grade ≥3 Any AE 268 (97.8) 243 (88.7) 270 (89.9) 230 (84.2) Neutropenia 172 (62.8) 131 (47.8) 180 (65.9) 130 (47.6) Fatigue 165 (60.2) 29 (10.6) 148 (54.2) 21 (7.7) Anemia 161 (58.8) 60 (21.9) 158 (57.9) 61 (22.3) Thrombocytopenia 122 (44.5) 39 (14.2) 133 (48.7) 32 (11.7) Diarrhea 119 (43.4) 11 (4.0) 125 (45.8) 15 (5.5) Neuropathy peripheral 112 (40.9) 20 (7.3) 81 (29.7) 18 (6.6) Nausea 107 (39.1) 11 (4.0) 121 (44.3) 7 (2.6) Edema peripheral 107 (39.1) 5 (1.8) 99 (36.3) 2 (0.7) Leukopenia 85 (31.0) 47 (17.2) 98 (35.9) 42 (15.4) Dermatitis 82 (29.9) 8 (2.9) 8 (2.9) 0 Vomiting 82 (29.9) 7 (2.6) 79 (28.9) 15 (5.5) Hepatic enzyme increased 75 (27.4) 35 (12.8) 72 (26.4) 24 (8.8) Pyrexia 74 (27.0) 6 (2.2) 64 (23.4) 2 (0.7) Abdominal pain 73 (26.6) 11 (4.0) 83 (30.4) 12 (4.4) Rash 71 (25.9) 5 (1.8) 23 (8.4) 1 (0.4) Alopecia 71 (25.9) 0 86 (31.5) 2 (0.7) Musculoskeletal pain 70 (25.5) 3 (1.3) 79 (28.9) 5 (1.8) Constipation 65 (23.7) 1 (0.4) 57 (20.9) 0 Hypokalemia 63 (23.0) 12 (4.4) 70 (25.6) 20 (7.3) Pruritus 61 (22.3) 0 23 (8.4) 0

PRESENTED BY: 28 Dr Vincent Picozzi Device-related AEs, n (%) TTFields + GnP (N=274) All grades Grade ≥3 Any AE 222 (81.0) 26 (9.5) Any serious AE 1 (0.4) 0 Any AE leading to TTFields discontinuation 23 (8.4) 7 (2.6) Any AE leading to death 0 0 AEs occurring in ≥2% of patients Dermatitis 76 (27.7) 8 (2.9) Rash 48 (17.5) 4 (1.5) Pruritus 41 (15.0) 0 Rash maculo-papular 33 (12.0) 3 (1.1) Erythema 29 (10.6) 0 Skin irritation 25 (9.1) 2 (0.7) Skin reaction 17 (6.2) 1 (0.4) Skin ulcer 14 (5.1) 1 (0.4) Blister 10 (3.6) 0 Fatigue 12 (4.4) 2 (0.7) Abdominal pain 9 (3.3) 0 Diarrhea 7 (2.6) 0 Skin injury 8 (2.9) 0 Thermal burn 6 (2.2) 0 AE, adverse event; GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor Treating Fields. Device-related adverse events • No new safety signals were observed • No deaths were attributed to TTFields • Skin AEs were the most common device-related AEs  Majority were grade 1/2 and manageable with appropriate skin-care routines  7.7% of patients reported a grade 3 skin AE

PRESENTED BY: Key Takeaway Points/Conclusions 29 Survival benefit for patients is supported by significantly improved QoL and pain-free survival* compared with GnP alone Dr Vincent Picozzi The only frequently reported TTFields toxicity was localized skin reactions *as the time to a ≥ 20-point increase from baseline on a patient-reported visual analogue scale for pain or death. GnP, gemcitabine/nab-paclitaxel; LA-PAC, locally advanced pancreatic adenocarcinoma; OS, overall survival; TTFields, Tumor Treating Fields. PANOVA-3 is the first phase 3 trial in patients with unresectable LA-PAC to show an OS benefit over gemcitabine/nab-paclitaxel PANOVA-3 establishes TTFields with GnP as a potential new standard paradigm for unresectable LA-PAC

PRESENTED BY: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study ascopubs.org QR code here Check out the accompanying podcast, “TTFields in Locally Advanced Pancreatic Adenocarcinoma,” with Drs. Eileen M. O’Reilly and Peter Li, located on the online publication’s main page or at asco.org/podcasts. Dr Vincent Picozzi

PRESENTED BY: 31 Special thank you to all participating patients, their families, and clinical research teams for your commitment and contributions. Dr Vincent Picozzi Acknowledgements Medical writing support for this presentation was provided by Chelsea Higgins, Janin Knop and Christine Mormont of Novocure and Christine el Jundi of Bioscript Group. We thank Prof. Daniel Von Hoff for his contributions to design, development of, and guidance on the trial. We thank Dr. Hani Babiker, chair of the P3 steering committee & co-first author for his unwavering support to this trial and to TTFields. This study was sponsored by Novocure. Editorial support funded by Novocure Thank you to all participating sites around the world Austria: Salzburg Uniklinik fur Innere Medizin, Landes-Krankenhaus Steyr, Medical University of Graz, Klinikum Klagenfurt am Wörthersee; Australia: Greenslopes Oncology, Westmead Hospital, Sydney Adventist Hospital, St. John of God Murdoch Hospital, Monash Health; Belgium: University of Leuven, Research UZ/KU Leuven, Clinique Universutaire Saint Luc - Institut Roi Albert; Brazil: Instituto Ribeiraopretano de Combate ao Cancer, Instituto Brasileiro de Controle do Cancer (IBCC), Hospital de Clínicas de Porto Alegre, COI, Ynova Pesquisa Clinica, Hospital de Caridade de Ijui (HCI), Centro de Pesquisa Clínica Multidisciplinar da Santa Casa de Porto Alegre, Hospital São Lucas da PUCRS, Oncoclinicas Rio de Janeiro S.A.’ Instituto D’Or de Pesquisa e Ensino – Matriz Rio de Janeiro, Instituto D’Or de Pesquisa e Ensino – Filial Salvador (Hospital São Rafael), Instituto D’Or de Pesquisa e Ensino; Canada: Centre Hospitalier Universitaire de Sherbrooke CIUSSS de l’Estrie – CHUS, London Health Science Center London Regional Cancer Program, Centre Hospitalier de l'Universite de Montreal- CHUM CIUSSS de l’Estrie – CHUS; People’s Republic of China: Beijing Cancer Hospital, Jilin Guowen Hospital, Henan Provincial People’s Hospital, Shanghai Changhai Hospital, Xingtai People’s Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xi'an Jiaotong University, Beijing University People's Hospital, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Shanxi Province Cancer Hospital, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Sun Yat- Sen Memorial Hospital of Sun Yat-Sen University, Guangdong Provincial People's Hospital, Bethune First Hospital of Jilin University, Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine, Linyi Cancer Hospital, Harbin Medical University Cancer Hospital, Beijing Union Medical College Hospital; Croatia: UHC Zagreb; Czech Republic: Olomouc Fakultni Nemocnice, Nemocnice Na Bulovce, General University Hospital in Prague, Nemocnice Novy Jicin, Masaryk Institute of Oncology; France: Institut de Cancérologie de l’Ouest (ICO), Hopital Saint-Antoine, Centre Léon Bérard, Hopital haut-Léveque CHU Bordeaux - Service d'Hépato- Gastroentérologie et d'Oncologie digestive, Strasbourg Oncologie Liberale, Hospital Group Bretagne Sud, Centre Armoricain d'Oncologie – CARIO, Centre de Lutte Contre le Cancer (CLCC) - Centre Paul Strauss; Germany: Klinik München Bogenhausen, Universitätsklinikum Ulm, Carl-von-Basedow-Klinikum Saalekreis, Medizinische Hochschule Hannover, Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Bonifatius Hospital Hematology and Oncology Lingen, Klinikum Chemnitz gGmbH; Hong Kong: Queen Mary Hospital; Hungary: Bacs-Kiskun County Teaching Hospital, Jasz-Nagykun-Szolnok Megyei Hetenyi Geza, National Institute of Oncology, Tolna County Balassa Janos Hospital, Békés Megyei Pándy Kálmán Kórháza Megyei Onkológiai Központja; Israel: Haifa Rambam Medical Center, Tel Aviv Sourasky Medical Center, Hadassah Medical Center, Rabin Medical Center, Sheba Pancreatic Cancer Center; Italy:Università Campus Bio-Medico, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Ospedale Civile Ss. Antonio e Biagio e Cesare Arrigo, Ospedale San Giovanni, Azienda Ospedaliero-Universitaria Careggi; Mexico: Accelerium Clinical Research, Centro Potosino de Investigación Médica, Mediadvance Clinical, Centro de Investigación Médica Aguascalientes (CIMA), FAICIC Clinical Research, Clinstile S.A de C.V., Centro de Estudios de Alta Especialidad de Sinaloa, Phylasis Clinicas Research, Hospitales Star Medica, PCR Toluca Corporativo Hospital Satelite, Clinica Integral Internacional de Oncologia, Hospital Angeles - Centro Medico del Potosi, Practice of Centro Hemato Oncologico Privado, Hospital Universitario "Dr. Jose Eleuterio Gonzalez“; Poland: M.Sklodowska-Curie Inst.of Oncol., Klinika Onkologii Uniwersytetu Medyczneg, Mrukmed Medical Center, Uniwersytecki Szpital Kliniczny we Wrocławiu, Oncology and Radiotherapy Clinic University Clinical Center Non-Invasive Medicine Center; South Korea: Chonnam National University Hwasun Hospital, Dong-A University Hospital, Gachon University Gil Hospital, Inha University Hospital, Keimyung University, Dongsan hospital, Korea University Guro Hospital, National Cancer Center, Samsung Medical Center, Seoul National University Bundang Hospital, The Catholic University of Korea, Seoul St. Mary's Hospital, Severance Hospital, Ajou University Hospital, CHA Bundang Medical Center; Spain: Vall d'Hebron Barcelona, Madrid, HM Hospitales CIOCC, Instituto Oncologico Dr. Rosell, Hospital Universitario Ramon Y Cajal Carretera de Colmenar Viejo, Hospital Regional Universitario de Málaga, Marqués de Valdecilla University Hospital, Elche Hospital General Universitario, Inst. Valenciano de Oncologia, Pamplona Clinica Universidad de Navarra,; Switzerland: Fribourg Hôpital, Winterthur Kantonsspital; USA: Tennessee Oncology, Cedars Sinai, Ochsner Clinic Foundation, Associated Neurologists of Southern Connecticut, University of Minnesota, The University of Arizona Cancer Center, Texas Oncology, Comprehensive Cancer Center of Nevada, Karmanos Cancer Center, Norton Cancer Institute, Beth Israel Deaconess Medical Center (BIDMC), Erlanger Health System, West Virginia University, Banner MD Anderson Cancer Center, Seattle Cancer Care Alliance, Pacific Cancer Medical Center, Virginia Mason Medical Center, Novant Health Oncology Specialists, HCA Midwest Division of Sarah Cannon Research Institute, Laura and Issac Perimutter Cancer Center at NYU Langone, Mount Sinai Comprehensive Cancer Center (MSCCC), Vita Medical Associates, Loyola University Chicago, University of Kansas Cancer Center (KUCC), Boca Raton Clinical Research Medical Center, Florida Hospital Tampa, Dignity Health Cancer Institute, Florida Cancer Specialists, Florida Cancer Specialists, Renown Regional Medical Center, Piedmont Cancer Institute (PCI), Nebraska Methodist Hospital, Geisinger Medical Center, North Shore University Health, University of Maryland Comprehensive Cancer Center, University of Oklahoma Health Sciences Center, Arizona Oncology Associates, Oncology and Hematology Associates of Southwest Virginia, Texas Oncology – Bedford, Texas Oncology – Tyler, Texas Oncology - El Paso Cancer, Baylor, Scott and White Medical Center, Cancer & Hematology Centers of Western Michigan, Florida Hospital Cancer Institute, Houston Methodist Cancer Center and Institute of Academic Medicine, Cotton O’Neil Cancer Center Stormont Vail Health Care, Illinois Cancer Specialist, Texas Oncology - Beaumont Mamie, Maryland Oncology Hematology, Willamette Valley Cancer Institution, NY Presbyterian Queens, Infirmary Health, White Plains Hospital, Vista Oncology Group, Sutter Institute for Medical Research, Rush University Medical Center, Methodist Richardson Cancer Center, UMass Memorial Hospital, Lynn Cancer Institute, Boca Raton Regional Hospital, Grandview Health, General Physician Cancer Care – Williamsville, Hematology Oncology Central Maine Medical Center (CMMC), Cancer Specialist of North Florida, Providence Medical Foundation, Gabrail Cancer Center Research, Toledo Clinic Cancer Center, OptumCare, Tennessee Cancer Specialists, Princeton Radiation Oncology (Regional Cancer Care Associates LLC), Bassett Cancer Institute, Ridley Tree Cancer Center, Mayo Clinic Jacksonville, St. Elizabeth Healthcare, St. Helena Healthcare - Martin O'Neil Cancer Center Scan to access JCO publication

© 2025 Novocure GmbH 33 path to regulatory approval Topline analysis Data presentation at ASCO Data publication in JCO FDA submission 2025 2026 TUV and PMDA submissions Commercial launch Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4Q4 REGULATORY REVIEW PERIODSUBMISSION ✓ ✓ ✓ REGULATORY REVIEW PERIODSUBMISSION

© 2025 Novocure GmbH 34 PANOVA-4 builds on promising clinical data for TTFields therapy with PD-(L)1 inhibitors PANOVA-4 phase 2 study delves deeper into TTFields therapy’s capabilities in pancreatic cancer • Studying TTFields therapy with atezolizumab + nab-paclitaxel / gemcitabine in metastatic pancreatic cancer • Primary endpoint: disease control rate • Fully enrolled, 12-month patient follow-up ongoing • Top-line data anticipated H1 2026

© 2025 Novocure GmbH 35 2025 key objectives, unlocking TTFields potential DRIVING COMMERCIAL ADOPTION ADVANCING CLINICAL PIPELINE DELIVERING PRODUCT INNOVATION NSCLC: drive global active patient growth and pursue reimbursement NSCLC: CE Mark achieved, launch underway in Germany • NSCLC: PMDA approval and launch in Japan  PANOVA-3: present and publish data • PANOVA-3: submit to FDA, CE Mark and PMDA • METIS: submit to FDA, publish clinical data • TRIDENT and PANOVA-4: patient follow up; prepare for H1 2026 top-line data  Launch MyNovocure patient app • New array utilized by every Optune Gio patient • Advance next gen torso array

PRESENTED BY: 37 Appendix Dr Vincent Picozzi

PRESENTED BY: Array Layouts 38 Dr Vincent Picozzi A) Epigastric-centered with the superior discs row at the level of the xiphoid B) Left hypochondriac-shifted to the left with the superior discs row at the level of the xiphoid C) Right hypochondriac-shifted to the right with the superior discs row at the level of the xiphoid D) Umbilical- centered with the superior discs row at the inferior border of the 10th costal cartilage

PRESENTED BY: Array Layouts – continued 39 Dr Vincent Picozzi E) Left lumbar-shifted to the left with the superior discs row at the inferior the 10th costal cartilage F) Right lumbar-shifted to the right with the superior discs row at the inferior border of the 10th costal cartilage. G) Large epigastric- centered with the superior discs row at the level of the xiphoid H) Large umbilical- centered with the inferior discs row below the umbilicus

PRESENTED BY: Secondary Endpoints in the mITT population 40 Dr Vincent Picozzi mITT TTFields + GnP GnP P-value Median PFS (95% CI) Events 11.2 (9.4, 13.1) 136 10.7 (9.1, 11.5) 121 0.183 HR = 0.84 (95% CI: 0.66, 1.08) 1-year PFS rate, median (95% CI) 48.5 (40.5, 56.0) 38.7 (30.5, 46.8) 0.044 PFS Local PFS mITT TTFields + GnP GnP P-value Median local PFS (95% CI) Events 12.9 (11.3, 15.1) 117 11.5 (9.8, 13.1) 101 0.194 HR = 0.84 (0.64. 1.10) 1-year local PFS rate, median (95% CI) 51.9 (44.8, 58.6) 41.8 (34.2, 49.2) 0.027 mITT TTFields + GnP GnP P-value Median distant PFS (95% CI) Events 15.6 (13.1, 18.4) 81 12.2 (11.3, 13.7) 88 0.017 HR = 0.69 (95% CI: 0.51, 0.94) 1-year distant PFS rate, median (95% CI) 64.4 (55.7, 71.8) 52.6 (43.4, 60.9) 0.013 Distant PFS (post-hoc) mITT TTFields + GnP GnP P-value Median pain-free survival (95% CI) Events 16.6 (11.0, 29.9) 79 9.2 (7.6, 12.9) 86 0.019 HR = 0.69 (95% CI: 0.50, 0.94) 1-year pain-free survival rate, Median (95% CI) 56.8 (48.1, 64.7) 45.8 (36.6, 54.6) 0.040 Pain-free survival

PRESENTED BY: Overall response rate (ITT population) 41 Dr Vincent Picozzi TTFields + GnP (n=244) GnP (n=243) Best overall response, n (%) CR 3 (1.2) 0 PR 85 (34.8) 73 (30.0) SD 142 (58.2) 150 (61.7) PD ORR, % (95% CI) 14 (5.7) 36.1 (30.0, 42.4) 20 (8.2) 30.0 (24.3, 36.2) Mean difference in ORR, % (95% CI) 1-sided p-value 6.0 (−2.4, 14.4) 0.094 Resectability rate, % (95% CI) 7.0% (4.3, 10.6) 10.1% (6.9, 14.2) CI, confidence interval; CR, complete response; GnP, gemcitabine/nab-paclitaxel; ITT, intent-to-treat population; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; TTFields, Tumor Treating Fields • ORR and resectability rate were not significantly improved with concomitant TTFields therapy • Resectability rate was comparable to other trials in this population

PRESENTED BY: Salvage Therapies 42 Dr Vincent Picozzi Summary of Salvage Systemic Therapies TTFields + GnP (N=285) GnP (N=286) Number of Subjects Having Salvage Systemic Therapies 146 (51.2) 134 (46.9) Fluorouracil 92 (32.3) 78 (27.3) Irinotecan hydrocholide 85 (29.8) 69 (24.1) Folinic acid 75 (26.3) 61 (21.3) Oxaliplatin 57 (20.0) 42 (14.7) Radiotherapy 48 (16.8) 44 (15.4) Gemcitabine Hydrochloride 29 (10.2) 24 (8.4) Capecitabine 27 (9.5) 23 (8.0) Paclitaxel Albumin 22 (7.7) 11 (3.8) Gimeracil; Oteracil; Tegafur 9 (3.2) 5 (1.7) Investigational Antineoplastic Drugs 8 (2.8) 5 (1.7) Traditional Medicine 3 (1.1) 4 (1.4) Cisplatin 3 (1.1) 2 (0.7)

PRESENTED BY: Limitations 43 • Investigator's assesment of CT scans for response determination • While protocol included a clear definition of resectability at baseline, there was no such guidance for follow up visits • Gender imbalance between both arms • High discontinuation rate within the first month in both arms • The median OS in the control arm is lower than in other phase 2 and 3 trials, albeit in line with RWE data • Open label trial Dr Vincent Picozzi